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Abstract 
Objectives: To determine socio-demographic and immunological status of anti-retroviral treatment (ART)-naïve HIV-
positive patients.  
Methods: This was a longitudinal survey of HIV-positive patients treated with ART at Felege-Hiwot Hospital. CD4 
cell counts were enumerated at baseline and after 6 months of treatment using FACS count (Becton Dickinson). Socio-
economic data were collected using pre tested questionnaires. 
Results: Three hundred sixty eight (62% female), with median age 30 years were enrolled. Of these, 207 (56.5%) were 
uneducated and 233 (66.8%) had monthly income ≤ 250 birr. Three hundred fifteen (85.6%) started ART within 6 
months of HIV diagnosis. The mean (95% CI) CD4 cell count at baseline was 153 (139-167); 156 (137-175) for 
females and 122 cells/µl (105-139) for males (p<0.01). At baseline, 280 (76.3%) and 134 (36.4%) patients had CD4 
cell count <200 and ≤ 100 cells/µl, respectively. Six months follow-up CD4 counts were enumerated for 225 (61%) 
patients and their mean CD4 cells increased from 143-261 cells/µl (p < 0.05) with a mean cell gain of 117 cells/µl. Of 
the 166 follow-up patients withCD4 count <200 cells/µl at baseline, 130 (78%) attained a higher CD4 cells count after 
treatment compared to 50 (85.6%) of the 59 with CD4 cell >200 cells/µl (p=0.21).  
Conclusion: In this setting, HIV patients started ART with lower mean CD4 cell counts of 153 cells/µl and most 
patients with low baseline CD4 cells (<200 cells/µl) counts didn’t achieve an increase in the number of CD4 cells after 
treatment. The majority of ART-naïve HIV patients were from low levels of education and with minimum monthly 
income. Appropriate interventions should be implemented to promote and enable HIV positive individuals to enter into 
ART programs as early as possible [Ethiop. J. Health Dev 2010;24(1):3-8]. 
 
Introduction 
An estimated 31 million adults worldwide were living 
with HIV and of these 2.3 million were newly infected 
with the virus and 1.7 million died of HIV/AIDS in 2008 
(1). Sixty seven percent of HIV infection worldwide, 
68% new cases among adults with 72% of AIDS related 
deaths were estimated in sub-Saharan Africa in 2008. 
According to the World Health Organization (WHO) 
estimation, nearly 3 million people living in low and 
middle-income countries (LMIC) were receiving 
Antiretroviral Therapy (ART) at the end of 2007 (2). 
According to the UNIAIDS/WHO update data the 
number of AIDS-related deaths has declined by over 
10% over the past five years due to antiretroviral 
treatment (1).   
 
In Ethiopia, approximately one million people are living 
with HIV which has become the leading cause of 
mortality among 15-49 years of age, that accounts for 
about 43% of all population in 2008 (3). ART was started 
in the country in 2003 and free ART was launched in 
2005. In 2009, 93 public hospitals, 47 private hospitals, 
12 military hospitals  and 292 health centers  and 3 non-
governmental  organization clinics were providing HIV 
care and treatment services in all regions of the country 
(4). The prevalence of HIV infection is the highest in 
Amhara regional state where this study was based 
compared to other parts of Ethiopia. In the region, more 
than 97,588 cases needed ART and only 38,067 (39%) 
were able to be treated in 17 hospitals and 62 selected 
health centers (5). 
 
HIV infection causes progressive depletion of CD4 cells, 
which leads to immunodeficiency syndrome with a wide 
range of opportunistic infections and malignancies that 
eventually leads to death. Several studies indicated that 
proper use of antiretroviral treatment substantially 
reduces morbidity, mortality and prolongs life 
expectancy of HIV/AIDS patients (1,6-8). However, 
there are numerous factors that could limit its 
effectiveness especially in resource limited settings. 
Studies indicated that the response of ART varies among 
population due to differences in viral subtype, host 
factors, co-infections, such as tuberculosis (TB), other 
bacterial diseases or socioeconomic status and 
environment (9-11).  
 
Various studies in sub-Saharan Africa and in low income 
settings reported that many HIV infected patients are 
accessing antiretroviral treatment program after 
developing advanced immunodeficiency (12). This study 
was conducted to explore the socio-demographic 
characteristics and immunological status of ART-naive 
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HIV- infected patients attending Felege Hiwot Referral 
Hospital, Northwest Ethiopia. 
 
Methods 
Study design and area 
A longitudinal study was done from September 2008 to 
August 2009 at Felege Hiwot Referral Hospital, that is 
one of the government sponsored ART centers at Bahir 




All volunteer ART-naïve HIV-infected individuals age 
above 15 years who were initiating ART were enrolled 
consecutively and followed for six months. During 
enrolment for ART, socio-demographic data including 
gender, age, income and educational status were recorded 
by ART trained physicians using a structured and pre 
tested questionnaire. Participants were asked when they 
were first tested for HIV and the reason why they were 
tested. 
 
CD4 cell counts 
At initiation of ART and after 6 months of treatment, 4 
ml venous blood was collected from each participant 
using K3 EDTA vacutainer tube. CD4 T cells and CD8 T 
cell counts were enumerated using FACS (Fluorescent 
Antibody Cell Sorter, Becton Dickinson). 
 
Statistical analysis  
Data were entered and analyzed using SPSS window 
version 16.  Categorical variables were tested by chi-




Ethical approval was secured from Research Ethics 
Committee of the College of Medicine and Health 
Science of Bahir Dar University as well as from Bahir 
Dar Regional Health Research Laboratory. Informed 




Among a total 368 patients recruited, 227 (61.6%) were 
females. The median age of the participants was 30 years 
(range 15- 65years) and 73.6% were age between 20 and 
40 years. The majority of the participants 207 (56.2%) 
were illiterate and had low economic status 233 (66.8%) 
as defined by their monthly income (Table 1). Among 
263(75.4%) the main reasons for being tested for HIV 
was related to experiencing repeated and/or persistent 
risky sexual behavior.  The time interval between the first 
HIV testing (knowing their HIV status) and date of 
staring ART was very short. Since the majority [315 
(85.6%)] of HIV patients started ART within 6 months 
and 14 (3.8%) between 6 months to 1 year from the date 
of diagnosis (Table 1). 
 
Common Opportunistic Infections and co-morbidities  
We have attempted to determine the common 
opportunistic infections, which are cause of morbidity 
and mortality among HIV-infected patients at baseline. In 
this study, at baseline, 327 (88.9%) HIV patients 
presented with common opportunistic infections. Of 
these, 143 (38.6%) had chronic diarrhea, 127 (34.5%) 
with TB, 113 (30.7%) with herpes zoster, 52 (14%) with 
Oro-pharyngeal candidiasis, 13 (3.5%) with pneumonia 
and 46 (12.5%) with other sexually transmitted infections 
(STI) as shown in (Table 2). 
 
Table 1:  Socio-demographic characteristics of ART 
naïve HIV patients at Feleg Hiwot Hospital, Ethiopia, 
2008 
Participants Characteristics  Frequency  
N (%) 
Time interval from HIV diagnosis to 
commencing ART (N = 368) 
 
Within 6 months  315 (85.6) 
 6 months to 1 year  14 (3.8) 
 1 to 2 years  22 (6) 
 2-3 years 13 (3.5) 
> 3 years 4 (1.4) 
 Education status (N = 368)  
No formal education   207 ( 56.2) 
Primary  (grade 1-6) 36 (9.7) 
Secondary complete (grade 7-12)  31 (8.4) 
High school complete (grade 12) 65 (17.6) 
Above high school (grade 12 +) 29 (7.8) 
Reason for getting HIV testing 
(N=349)* 
 
Due to repeated illness  263 (75.4) 
Risk sexual behaviors 41 (11.7) 
After death of  spouse   11 (3.2) 
Premarital testing 7 (2) 
Provider  initiative counseling and testing 10 (2.86) 
Others 17 (4.8) 
Income per month ( Ethiopian birr) 
(N=349)* 
 
≤ 250  233 (66.8) 
251-500 53 (15.2) 
501-1000 51 (14.6) 
≥1001 12 (3.4) 
*Reason for testing and income was not recorded for 19 
patients, N = number, ART = Anti-retroviral therapy 
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Figure 1: The distribution of CD4 cell count among untreated HIV-positive patients at initiation of  
ART at Felege Hiwot Hospital, Ethiopia, 2008. 
 
 
Table 2:  Number of ART naïve HIV patients diagnosed with common opportunistic infections 
by sex at Felege Hiwot Hospital, Ethiopia, 2008 
           Sex Opportunistic infections N (%) 
Male N (%) Female N (%) P value  Total  
Tuberculosis  62 (44) 65 (28.6) 0.003 127 (34.5) 
Chronic diarrhea 60 (42.5) 83 (36.6) 0.63 143 (38.6) 
Herpes Zoster 41 (29) 72 (31.7) 0.24 113 (30.7) 
Oro-pharyngeal Candidiasis 17 (12.5) 35 (15.4) 0.36 52 (14) 
Other Sexually transmitted 
infections 
21 (15) 25 (11) 0.27 46 (12.5) 
Pneumonia 6 (4.2) 7(3) 0.76 13 (3.5) 
Total  141 227  368 
 
 
CD4 cell counts  
At baseline, the mean CD4 cell count for both sexes was 
153cells/µl (95% CI: 139-167). The mean CD4 cell count 
was 156 cells/µl (95% CI: 137-175) for females and 122 
cells/µl (95% CI: 105-139) for males (P = 0.002).  Two 
hundred and eighty (76.3%) of the HIV- infected patients 
had CD4 cell count of less than 200 cells/µl and therefore 
had AIDS and 134 (36.4%) had CD4 cell counts ≤ 100 
cells/ µl.  The overall mean CD4/ CD8 T cell ratio was 
0.22.   One hundred twelve (30.4%) patients had 
CD4/CD8 cell ratio between 0.01-0.09. 
 
Patient follow-up  
Follow-up CD4 cell counts were enumerated for only 
225 (61%) HIV positive patients as 143 (38.8%) patients 
were lost to follow-up at 6 months of treatment. The 
mean CD4 cell count for these 225 follow-up patients 
increased from 143 at baseline to 261 cells/µl (95% CI: 
240-282) at 6 month of treatment as shown in (Table 5). 
The mean number of CD4 cell gained was 117 cells/µl in 
81.8% (78% from patients who had low baseline CD4 
cells count or <200 cells/µl) follow-up cases. Seventy 
two (32%) HIV positive patients failed to attain CD4 cell 
count above 200 cells/µl after 6-month of treatment. Of 
these, 61 (84%) were from those with low baseline CD4 
cell count (< 200 cells/ µl). Forty one (18.2 %) patients 
had a lower CD4 cell count after six month of treatment 
compared to the baseline count. Among 166 follow-up 
HIV patients who had CD4 count of <200 cells/µl at 
baseline, 130 (78%) showed an increment in CD4 cells 
count whereas, among 59 follow-up patients who had 
CD4 cell count of >200 cells/µl at baseline, 51 (86%) had 
increased CD4 cells count although the difference was 
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Table 3: CD4 cell count among ART naïve HIV patients by age at Felege Hiwot Hospital, 
Ethiopia, 2008 
                                    Age groups (year) CD4 count cells/µl 
At baseline < 20 20-29  30-39  40-49 50-59 ≥ 60 Total 
< 50 3 16 27 15 2 - 63 
50-99 1 24 28 10 8 - 71 
100-149 1 26 27 9 2 - 65 
150-199 3 30 26 14 7 2 82 
200-249 - 11 13 10 4 - 38 
250-299 1 6 9 - 1 - 17 
300-349 - 7 5 1 - - 13 
350-399 - 3 4 - - - 7 
≥ 400 2 5 4 1 - - 12 
Total  11 128 143 60 24 2 368 
 
 
Table 4: Mean baseline CD4 cell count of ART-naïve HIV positive patients by gender  
at Feleg Hiwot Hospital, Ethiopia, 2008 
Mean CD4/CD8 cells 
Sex CD4 cells/µl CD8 cells/µl CD4/CD8 ratio 
Female (N = 227) 156 809 0.23 
Male (N = 141) 122 829 0.2 
P value  0.002 >0.05  
Average 153 833 0.22 
 
 
Table 5: CD4 cell counts at baseline and after six month ART of HIV patients at Felege Hiwot  
referral hospital, Ethiopia, 2008 
CD4 cell/µl At baseline (N = 368) 
N (%) 
At six month follow- up 
(N= 225)* N(%) 
P value 
<100 134 (36.4) 18 (8) <0.001 
100-200 147 (39.9) 54 (24) <0.001 
201-300 55 (14.9) 60 (26.6) <0.001 
301-400 20 (5.4) 37 (16.4) <0.001 
≥400 12 (3.3) 56  (25) <0.001 
Mean CD4 cells (95% CI) 153 (139-167) 261 (240-282) <0.05 
*143 patients were lost to follow up 
 
Discussion 
In this study, the majority of ART-naïve HIV patients 
were females. A similar finding was reported by 
Braitsein et al; (11) from South Africa who stated that 
ART-naïve patients in low-income countries were more 
likely to be females. This is because females are 
biologically and socially more vulnerable to HIV 
infection in the developing countries (13). Most of the 
HIV infected patients enrolled in our study were young 
age between 20 and 40 years old who were sexually more 
active and thus have a higher risk of infection compared 
to the other age groups (13). Higher proportions of ART- 
naïve HIV infected patients had low educational level 
and were from minimum income groups. These findings 
conform previous reports from the same study area (14) 
and elsewhere in Ethiopia which reported that HIV 
prevalence decreases significantly with increasing level 
of education (15). 
 
At baseline, the mean CD4 cell count of ART-naïve HIV 
infected patients was lower (153 cells/µl) than the reports 
from other countries (16). This could be due to delayed 
presentation and/or testing, differences in educational and 
socio-economic levels. Moreover, Tsegaye et al; (17) 
reported that healthy HIV-negative Ethiopians had lower 
mean CD4 cell counts (775/µl) than other Africans and 
individuals from Western countries. 
 
In our study, female HIV patients had higher mean CD4 
cell counts than male (p < 0.002) before ART was 
initiated. This is consistent with Kumarasamy et al; (18) 
report from India. This difference could be due to several 
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reasons; HIV associated TB could be the contributing  
factor for the low CD4 count in males as  the proportion 
of patients having TB was  significantly higher in male 
HIV positive patients than females (p=0.003). In addition, 
it may be due to a sex-related difference in the overall 
CD4 counts among males and females as reported by 
Tsegay et al; (17). HIV sero-negative Ethiopian females 
had relatively higher CD4 cell counts than HIV sero-
negative males. 
 
Our data indicates that the majority of HIV patients 
started antiretroviral treatment with more advanced 
immunodeficiency status. Since the majority (76.3%) of 
HIV patients had AIDS as defined by their CD4 cell 
counts < 200 cells/µl, as shown in indicating advanced 
immune suppression at initiation of ART. This was 
significantly higher when compared to the studies 
conducted in Nigeria, south eastern United States and 
Thailand which reported a lower rate of AIDS at the 
initiation of ART (19-21). 
 
Therefore, in the study hospital, delayed enrollment in 
ART program could be attributed by several factors. 
Moreover, Kiflie et al; (22) in the same hospital reported 
that more than 28.8% of HIV infected patients who were 
eligible to be on ART but never started ART, might be 
related to poor quality of HIV testing services in the 
existing delivery sites. The other possible factor may be 
due to fear of stigma.  In Ethiopia, only one third of HIV 
infected persons disclosed their HIV status to their 
partner (23) further compromising the utilization of the 
counseling and testing and ART services. Moreover, it 
was noted that  most (75.4%) of HIV infected patients 
seeking medical care when they had debilitating 
conditions and recurrent illnesses and  the majority of 
them have started ART within 6 months of diagnosis. A 
similar observation was made among South Africans 
where patients stared ART program with advanced 
immunodeficiency status (24). These findings indicate 
urgent need to promote early and enhanced HIV testing 
to enable HIV/AIDS patients to benefit from the 
expanding ART services. 
 
The limitation of this study was a higher dropout rate as 
143 (38.8%) patients were lost to follow-up at 6 months 
of treatment. However, in the same hospital, about 36% 
patients were failed to follow-up because of multiple 
factors which were documented (25). Phone calls were 
used to contact patients but we were unable to actively 
trace lost to follow-up cases. Some of the reasons for the 
failure to follow-up were serious illness and deteriorating 
health situation, change in address, undocumented 
transfer out to other hospitals, lack of support, financial 
reasons or death. Several studies reported that the 
proportion of patients on ART lost to follow-up varied in 
different settings ranging from 19% to 44% (11, 19). Our 
data indicated that loss to follow-up would be an 
important issue in ART program in resource limited 
countries and shouldn’t be overlooked during the 
initiation and expansion of the ART program. Tracing 
patients using only phone calls may not be feasible 
option in such areas where the majority of patients 
frequently change their addresses due to several reasons 
including stigma, socio-economic stress and luck of 
support. 
 
The mean CD4 cell count for 225 follow-up cases 
increased from 143 to 261 cells/ µl (95% CI: 240-282) 
after 6 month of treatment. This was comparable with 
report of Gautam et al; (26) in India. However, among 
treatment-naïve HIV patients, 72 (32%) failed to attain 
CD4 cell count above 200 cells/µl at 6 months. Lower 
CD4 cell counts (< 200 cell/µl) before staring ART had 
significantly associated with failure to attain CD4 cell 
count recovery as the majority of the 61 (84%) of  
patients whose CD4 cell count remained < 200 cells/µl at 
6 month were from those group with low baseline CD4 
cell count. A higher proportion of patients with baseline 
CD4 count > 200 cells/µl had increased CD4 cells count 
after 6 months of treatment than those with a lower 
baseline CD4 counts. Actually the difference was not 
significant. Lower baseline CD4 cell counts therefore 
may correlate with poor immune responses and thus 
determine the degree of morbidity and mortality related 
to HIV/AIDS as reported by other studies too (27-28). 
 
In conclusion, in our setting, although good CD4 cells 
recovery in response to ART was documented in more 
than 81% of follow-up cases, HIV-positive patients were 
enrolled in ART program at decreased CD4 cells levels. 
Therefore, interventions need to be designed to promote 
early HIV testing and early enrollment of HIV infected 
individuals into ART services. As socio-demographic 
factors and lack of awareness about ART services, fear of 
stigma and discrimination compromise the utilization of 
ART program, improving public awareness by advocacy 
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